Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926531 | 0.88 | ITGB1 (0.51) | ADAMTS5MMP2ITGB1ITGA4CA12 | |
| SCHEMBL5926711 | 0.87 | ITGB1 (0.50) | ADAMTS5MMP2ITGB1ITGA4CA12 | |
| SCHEMBL5926872 | 0.86 | ADAMTS5 (0.44) | ADAMTS5 | |
| SCHEMBL5926611 | 0.84 | MMP1 (0.51) | ADAMTS5MMP2ITGB1ITGA4CA12 | |
| SCHEMBL8337901 | 0.83 | ITGB1 (0.47) | ADAMTS5MMP2ITGB1ITGA4CA12 | |
| SCHEMBL5926499 | 0.83 | ITGB1 (0.47) | ADAMTS5MMP2ITGB1ITGA4CA12 | |
| SCHEMBL5927336 | 0.82 | ITGB1 (0.47) | ITGB1ITGA4ITGB7ERAP1GPR34 | |
| SCHEMBL5927175 | 0.81 | ITGB1 (0.47) | ADAMTS5MMP2ITGB1ITGA4ITGB7 | |
| SCHEMBL5926684 | 0.81 | ITGB1 (0.47) | ITGB1ITGA4ITGB7ERAP1GPR34 | |
| SCHEMBL8337414 | 0.80 | ITGB1 (0.44) | ADAMTS5MMP2ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ADAMTS5 65/4885MMP2 258/4885ITGB1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.